SI1458888T1 - Metode zdravljenja psihoze in shizofrenije na osnovi polimorfizmov gena cntf - Google Patents
Metode zdravljenja psihoze in shizofrenije na osnovi polimorfizmov gena cntfInfo
- Publication number
- SI1458888T1 SI1458888T1 SI200230940T SI200230940T SI1458888T1 SI 1458888 T1 SI1458888 T1 SI 1458888T1 SI 200230940 T SI200230940 T SI 200230940T SI 200230940 T SI200230940 T SI 200230940T SI 1458888 T1 SI1458888 T1 SI 1458888T1
- Authority
- SI
- Slovenia
- Prior art keywords
- polymorphisms
- methods
- cntf gene
- treating psychosis
- schizophrenia based
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33983501P | 2001-12-10 | 2001-12-10 | |
PCT/EP2002/013937 WO2003054226A2 (en) | 2001-12-10 | 2002-12-09 | Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene |
EP02791794A EP1458888B1 (en) | 2001-12-10 | 2002-12-09 | Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1458888T1 true SI1458888T1 (sl) | 2011-07-29 |
Family
ID=23330814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200230940T SI1458888T1 (sl) | 2001-12-10 | 2002-12-09 | Metode zdravljenja psihoze in shizofrenije na osnovi polimorfizmov gena cntf |
Country Status (16)
Country | Link |
---|---|
US (3) | US20050059006A1 (sl) |
EP (1) | EP1458888B1 (sl) |
JP (2) | JP2005512576A (sl) |
CN (1) | CN1612941B (sl) |
AT (1) | ATE503845T1 (sl) |
AU (1) | AU2002358110A1 (sl) |
BR (1) | BRPI0214821B8 (sl) |
CA (1) | CA2468972A1 (sl) |
CY (1) | CY1111594T1 (sl) |
DE (1) | DE60239634D1 (sl) |
DK (1) | DK1458888T3 (sl) |
ES (1) | ES2364037T3 (sl) |
HK (1) | HK1069413A1 (sl) |
PT (1) | PT1458888E (sl) |
SI (1) | SI1458888T1 (sl) |
WO (1) | WO2003054226A2 (sl) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE503845T1 (de) * | 2001-12-10 | 2011-04-15 | Novartis Pharma Gmbh | Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen |
US20100063093A1 (en) | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
JP2008514731A (ja) | 2004-09-30 | 2008-05-08 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | イロペリドンの投与方法 |
BRPI0711872A2 (pt) | 2006-05-22 | 2011-12-06 | Vanda Pharmaceuticals Inc | tratamento para distúrbios depressivos |
US20080249103A1 (en) * | 2006-11-15 | 2008-10-09 | Sirtris Pharmaceuticals, Inc. | Sirtuin polymorphisms and methods of use thereof |
EP2152917B1 (en) | 2007-05-18 | 2016-03-23 | Vanda Pharmaceuticals Inc. | Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms |
EP2198049A1 (en) * | 2007-09-10 | 2010-06-23 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on snp genotype |
JP5653753B2 (ja) * | 2007-09-10 | 2015-01-14 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Snp遺伝子型に基づくqt延長の予測 |
ES2527515T3 (es) | 2007-12-13 | 2015-01-26 | Vanda Pharmaceuticals Inc. | Método y composición para tratar una afección mediada por un adrenoceptor alfa |
MX2010006521A (es) | 2007-12-13 | 2010-08-10 | Vanda Pharmaceuticals Inc | Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina. |
EP2570501A3 (en) * | 2008-01-02 | 2013-04-10 | Suregene Llc | Genetic markers of mental illness |
EP2581453A3 (en) * | 2008-01-17 | 2013-07-10 | Suregene Llc | Genetic Markers of Mental Illness |
JP2012507297A (ja) * | 2008-10-29 | 2012-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Erbb4遺伝子の多型に基づく精神病及び統合失調症の治療法 |
EP2430183B1 (en) | 2009-05-15 | 2014-12-17 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
ES2677474T3 (es) | 2012-03-14 | 2018-08-02 | Vanda Pharmaceuticals Inc. | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos |
US10877498B2 (en) * | 2017-10-27 | 2020-12-29 | Brasscraft Manufacturing Company | Excess flow and thermal valve |
EP3844758A1 (en) * | 2018-08-28 | 2021-07-07 | Koninklijke Philips N.V. | Method for assessing genome alignment basis |
US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
US20220290237A1 (en) * | 2019-04-24 | 2022-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the response of antipsychotic drugs |
CN110184345B (zh) * | 2019-07-11 | 2020-05-05 | 南京先声医学检验有限公司 | 用于检测精神及神经类疾病用药相关snp位点的引物组、应用、产品及方法 |
CN111187829A (zh) * | 2020-02-24 | 2020-05-22 | 内蒙古医科大学 | Lp基因启动子区甲基化检测引物与检测方法及其应用 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4478832A (en) * | 1982-06-28 | 1984-10-23 | Chevron Research Company | Pesticidal O-(N-alkoxy-substituted-benzimidoyl)-phosphorus esters and thioesters |
US5610035A (en) * | 1983-12-05 | 1997-03-11 | Institut Pasteur Centre National De La Recherche Scientific | Methods for the preparation of hybridomas producing lymphadenopathy-associated virus (LAV) GP110-specific monoclonal antibodies and methods for the purification of GP110 employing said monoclonal antibodies |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4843155A (en) * | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
JP2846018B2 (ja) | 1988-01-21 | 1999-01-13 | ジェネンテク,インコーポレイテッド | 核酸配列の増幅および検出 |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
WO1989010414A1 (en) | 1988-04-28 | 1989-11-02 | Robert Bruce Wallace | AMPLIFIED SEQUENCE POLYMORPHISMS (ASPs) |
US5130238A (en) * | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
ATE138106T1 (de) | 1988-07-20 | 1996-06-15 | David Segev | Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen |
ES2136059T5 (es) | 1989-02-13 | 2005-02-16 | Geneco Pty. Ltd. | Deteccion de una secuencia de acidos nucleicos o de un cambio en la misma. |
GB8908085D0 (en) * | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
US5238945A (en) * | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5302509A (en) * | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
IE903130A1 (en) * | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
US5169766A (en) * | 1991-06-14 | 1992-12-08 | Life Technologies, Inc. | Amplification of nucleic acid molecules |
US5846717A (en) * | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
JP3236295B2 (ja) * | 1991-09-24 | 2001-12-10 | ケイヘーネ・エヌ・ベー | 選択的な制限断片増幅:一般的なdnaフィンガプリント法 |
DE69329800D1 (de) | 1992-04-27 | 2001-02-01 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5605798A (en) * | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US5610053A (en) * | 1993-04-07 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
AU8126694A (en) | 1993-10-26 | 1995-05-22 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
IL108159A (en) | 1993-12-23 | 1998-02-08 | Orgenics Ltd | Apparatus for separation, concentration and detection of target molecules in liquid sample |
WO1995021271A1 (en) * | 1994-02-07 | 1995-08-10 | Molecular Tool, Inc. | Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis |
US5578832A (en) * | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US5539083A (en) * | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5854033A (en) * | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US5866404A (en) * | 1995-12-06 | 1999-02-02 | Yale University | Yeast-bacteria shuttle vector |
IL124967A (en) * | 1995-12-18 | 2000-07-26 | Univ Washington | Method for nucleic acid analysis using fluorescence resonance energy transfer |
DE69735112T2 (de) | 1996-11-06 | 2006-09-07 | Sequenom, Inc., San Diego | Verfahren zur Analyse und Vorrichtung |
AU746737B2 (en) | 1996-11-06 | 2002-05-02 | Sequenom, Inc. | Compositions and methods for immobilizing nucleic acids to solid supports |
EP1224322A2 (en) * | 1999-02-22 | 2002-07-24 | Variagenics, Inc. | Gene sequence variations with utility in determining the treatment of disease |
US20040171056A1 (en) * | 1999-02-22 | 2004-09-02 | Variagenics, Inc., A Delaware Corporation | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
JP2000346828A (ja) * | 1999-06-02 | 2000-12-15 | Hitachi Ltd | 電気泳動装置 |
AU5638600A (en) | 1999-06-25 | 2001-01-31 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
ATE463259T1 (de) * | 1999-08-26 | 2010-04-15 | Takeda Pharmaceutical | Nasenschleimhaut haftende matrix |
JP4632499B2 (ja) * | 1999-08-26 | 2011-02-16 | 武田薬品工業株式会社 | 鼻粘膜付着マトリックス |
JP3324594B2 (ja) * | 1999-12-20 | 2002-09-17 | 株式会社日立製作所 | バイオ製品の品質保証方法及びバイオ情報の配信方法 |
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
ATE503845T1 (de) * | 2001-12-10 | 2011-04-15 | Novartis Pharma Gmbh | Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen |
AU2003302442A1 (en) | 2002-11-25 | 2004-06-18 | Michael Leslie Harris | Multi flush toilet cistern |
US7851069B2 (en) | 2005-11-18 | 2010-12-14 | Federal Mogul World-Wide, Inc. | Heat shield with integral attachment flanges |
-
2002
- 2002-12-09 AT AT02791794T patent/ATE503845T1/de active
- 2002-12-09 SI SI200230940T patent/SI1458888T1/sl unknown
- 2002-12-09 DK DK02791794.7T patent/DK1458888T3/da active
- 2002-12-09 EP EP02791794A patent/EP1458888B1/en not_active Expired - Lifetime
- 2002-12-09 PT PT02791794T patent/PT1458888E/pt unknown
- 2002-12-09 CN CN028269411A patent/CN1612941B/zh not_active Expired - Lifetime
- 2002-12-09 WO PCT/EP2002/013937 patent/WO2003054226A2/en active Application Filing
- 2002-12-09 DE DE60239634T patent/DE60239634D1/de not_active Expired - Lifetime
- 2002-12-09 ES ES02791794T patent/ES2364037T3/es not_active Expired - Lifetime
- 2002-12-09 JP JP2003554926A patent/JP2005512576A/ja not_active Withdrawn
- 2002-12-09 AU AU2002358110A patent/AU2002358110A1/en not_active Abandoned
- 2002-12-09 BR BRPI0214821A patent/BRPI0214821B8/pt not_active IP Right Cessation
- 2002-12-09 CA CA2468972A patent/CA2468972A1/en not_active Abandoned
- 2002-12-09 US US10/497,503 patent/US20050059006A1/en not_active Abandoned
-
2005
- 2005-03-08 HK HK05102010.7A patent/HK1069413A1/xx not_active IP Right Cessation
-
2007
- 2007-05-29 US US11/754,470 patent/US20080027106A1/en not_active Abandoned
-
2009
- 2009-06-03 US US12/477,469 patent/US8460867B2/en not_active Expired - Lifetime
-
2010
- 2010-07-12 JP JP2010157563A patent/JP5785697B2/ja not_active Expired - Fee Related
-
2011
- 2011-06-27 CY CY20111100608T patent/CY1111594T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1458888A2 (en) | 2004-09-22 |
US20050059006A1 (en) | 2005-03-17 |
HK1069413A1 (en) | 2005-05-20 |
CN1612941B (zh) | 2011-11-16 |
JP2005512576A (ja) | 2005-05-12 |
PT1458888E (pt) | 2011-06-01 |
BR0214821A (pt) | 2004-11-03 |
EP1458888B1 (en) | 2011-03-30 |
CA2468972A1 (en) | 2003-07-03 |
WO2003054226A2 (en) | 2003-07-03 |
JP2011006422A (ja) | 2011-01-13 |
BRPI0214821B8 (pt) | 2021-07-27 |
US20080027106A1 (en) | 2008-01-31 |
AU2002358110A8 (en) | 2003-07-09 |
CY1111594T1 (el) | 2015-10-07 |
ATE503845T1 (de) | 2011-04-15 |
DE60239634D1 (de) | 2011-05-12 |
AU2002358110A1 (en) | 2003-07-09 |
DK1458888T3 (da) | 2011-06-20 |
ES2364037T3 (es) | 2011-08-23 |
BRPI0214821B1 (pt) | 2015-07-07 |
JP5785697B2 (ja) | 2015-09-30 |
WO2003054226A3 (en) | 2004-04-01 |
CN1612941A (zh) | 2005-05-04 |
US20090239908A1 (en) | 2009-09-24 |
US8460867B2 (en) | 2013-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1069413A1 (en) | Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene | |
BG66289B1 (en) | Combination of epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases | |
SI1572095T1 (sl) | Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv | |
SE9900100D0 (sv) | New compounds | |
HK1016893A1 (en) | Agent for treating neurodegenerative disorders | |
GB0117645D0 (en) | Therapeutic stratergies for prevention and treatment of alzheimers disease | |
AU2003284968A8 (en) | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease | |
HUP0402629A3 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
EP1490050A4 (en) | METHOD FOR TREATING ALZHEIMER AND COGNITIVE IMPROVEMENT | |
WO2003038123A3 (en) | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene | |
IL166466A0 (en) | Methods for the treatment of dementia based on apoe genotype | |
IL162408A0 (en) | Use of pramipexole to treat amyotrophic lateral scelrosis | |
WO2002102297A3 (en) | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders | |
WO2002066672A3 (en) | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists | |
HK1040908A1 (en) | Use of optically pure (R)-tofisopam for treating and preventing anxiety disorders. | |
AU2003285482A1 (en) | Methods and means for the treatment of inflammatory disorders involving genotyping of the 5, 10- methylenetetrahydrofolate reductase (mthfr) gene | |
IL137007A0 (en) | Compounds with growth hormone releasing properties | |
ZA200405173B (en) | 2'-halo-3',5'-dialkoxyphen-1'yl-imino-2-imidazoline derivatives and the use thereof for the treatment of urinary incontinence. | |
AU7402600A (en) | New sequence variants of the human beta1-adrenoreceptor genes and use thereof | |
ZA200205484B (en) | New therapeutic combinations of (S)-2-(benzylaminomethyl)-2,3,8,9,-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders. | |
MXPA04001309A (es) | Uso de sps o mch-r para identificar desordenes geneticos al mantener el peso corporal normal. | |
HUP0202416A3 (en) | Novel pharmaceutical combination and it's use for the treatment of certain cardiovascular disorders | |
EP1441684A4 (en) | METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING 313, 333, 5464, 18817 OR 33524 | |
MA25618A1 (fr) | Procede original d'elimination biologique integree du carbone, de l'azote et du phosphore | |
UA36524A (uk) | Спосіб проведення реабілітаційно-оздоровчих процедур, що засновані на використанні біологічного зворотного зв'язку, та апаратний комплекс для його здійснення |